{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:48:02Z","timestamp":1791110882305,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment option for peritoneal metastases (PM) from colorectal carcinoma (CRC). Because of considerable morbidity, optimal patient selection is essential. This study was designed to determine the impact of the onset of PM (synchronous vs. metachronous) on survival outcomes after CRS-HIPEC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients undergoing CRS-HIPEC for colorectal PM in two academic centers in the Netherlands between 2010 and 2020 were eligible for inclusion. Patients were classified as synchronous (s-PM, i.e., diagnosis at time of presentation, staging, or primary surgery) or metachronous onset (m-PM, i.e., diagnosis during follow-up) of colorectal PM. Survival outcomes were compared between groups by Kaplan\u2013Meier survival and Cox regression analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 390 included patients, 179 (45.9%) had synchronous onset of colorectal PM. These patients more often presented with higher TN-stage and poor differentiation\/signet cell histology. Treatment with perioperative chemotherapy was more common in s-PM patients. m-PM patients experienced more serious postoperative complications (Clavien-Dindo \u2265 III). There was no significant difference in disease-free survival (DFS) between s-PM (median 9 months, interquartile range [IQR] 5\u201315) and m-PM patients (median 8 months, IQR 5\u201317). Overall survival (OS) was significantly shorter for s-PM (median 28 months, IQR 11\u201348) versus m-PM patients (median 33 months, IQR 18\u201366, <jats:italic>p<\/jats:italic> = 0.049). Synchronous onset of PM was not independently associated with OS in a multivariable analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Synchronous onset of colorectal PM was associated with poor tumor characteristics and more advanced disease, but was not an independent predictor of survival outcomes after CRS-HIPEC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-022-11805-9","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T16:08:40Z","timestamp":1651766920000},"page":"6566-6576","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in Patients with Synchronous Versus Metachronous Onset of Peritoneal Metastases of Colorectal Carcinoma"],"prefix":"10.1245","volume":"29","author":[{"given":"Michelle V.","family":"Dietz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Job P.","family":"van Kooten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra R. M.","family":"Brandt-Kerkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas J. A.","family":"Bremers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes H. W.","family":"de Wilt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip R.","family":"de Reuver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva V. E.","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,5]]},"reference":[{"key":"11805_CR1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-10190-z","author":"C Bakkers","year":"2021","unstructured":"Bakkers C, Lurvink RJ, Rijken A, et al. Treatment strategies and prognosis of patients with synchronous or metachronous colorectal peritoneal metastases: a population-based study. Ann Surg Oncol. 2021. https:\/\/doi.org\/10.1245\/s10434-021-10190-z.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"11805_CR2","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/bjs.8679","volume":"99","author":"J Segelman","year":"2012","unstructured":"Segelman J, Granath F, Holm T, et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012;99(5):699\u2013705.\u00a0https:\/\/doi.org\/10.1002\/bjs.8679.","journal-title":"Br J Surg"},{"issue":"5","key":"11805_CR3","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.ejso.2020.11.135","volume":"47","author":"RJ Lurvink","year":"2021","unstructured":"Lurvink RJ, Bakkers C, Rijken A, et al. Increase in the incidence of synchronous and metachronous peritoneal metastases in patients with colorectal cancer: a nationwide study. Eur J Surg Oncol. 2021;47(5):1026\u201333.\u00a0https:\/\/doi.org\/10.1016\/j.ejso.2020.11.135.","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"11805_CR4","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/s1470-2045(16)30500-9","volume":"17","author":"J Franko","year":"2016","unstructured":"Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17(12):1709\u201319.\u00a0https:\/\/doi.org\/10.1016\/s1470-2045(16)30500-9.","journal-title":"Lancet Oncol"},{"issue":"9","key":"11805_CR5","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","volume":"15","author":"V Verwaal","year":"2008","unstructured":"Verwaal V, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-Year Follow-up of Randomized Trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426\u201332.\u00a0https:\/\/doi.org\/10.1245\/s10434-008-9966-2.","journal-title":"Ann Surg Oncol"},{"key":"11805_CR6","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1245\/s10434-009-0487-4","volume":"16","author":"C Cao","year":"2009","unstructured":"Cao C, Yan TD, Black D, Morris DL. A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2009;16:2152\u201365.\u00a0https:\/\/doi.org\/10.1245\/s10434-009-0487-4.","journal-title":"Ann Surg Oncol"},{"key":"11805_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/jco.2009.23.9285","volume":"28","author":"D Elias","year":"2010","unstructured":"Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63\u201386.\u00a0https:\/\/doi.org\/10.1200\/jco.2009.23.9285.","journal-title":"J Clin Oncol"},{"key":"11805_CR8","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1002\/cncr.25116","volume":"116","author":"J Franko","year":"2010","unstructured":"Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116:3756\u201362.\u00a0https:\/\/doi.org\/10.1002\/cncr.25116.","journal-title":"Cancer"},{"key":"11805_CR9","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1245\/s10434-012-2264-z","volume":"19","author":"D Hompes","year":"2012","unstructured":"Hompes D, D\u2019Hoore A, van Cutsem E, et al. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: A Belgian Multicentre Prospective Phase II Clinical Study. Ann Surg Oncol. 2012;19:2186\u201394.\u00a0https:\/\/doi.org\/10.1245\/s10434-012-2264-z.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"11805_CR10","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/s1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366.\u00a0https:\/\/doi.org\/10.1016\/s1470-2045(20)30599-4.","journal-title":"Lancet Oncol"},{"issue":"16","key":"11805_CR11","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1200\/jco.2004.10.012","volume":"22","author":"O Glehen","year":"2004","unstructured":"Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284\u201392.\u00a0https:\/\/doi.org\/10.1200\/jco.2004.10.012.","journal-title":"J Clin Oncol"},{"key":"11805_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/bjs5.50179","volume":"3","author":"S Hallam","year":"2019","unstructured":"Hallam S, Tyler R, Price M, Beggs A, Youssef H. Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy. BJS Open. 2019;3:585\u201394.\u00a0https:\/\/doi.org\/10.1002\/bjs5.50179.","journal-title":"BJS Open"},{"issue":"2","key":"11805_CR13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1245\/s10434-008-0234-2","volume":"16","author":"J-L Koh","year":"2009","unstructured":"Koh J-L, Yan TD, Glenn D, Morris DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2009;16(2):327\u201333.\u00a0https:\/\/doi.org\/10.1245\/s10434-008-0234-2.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"11805_CR14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","volume":"230","author":"Y Fong","year":"1999","unstructured":"Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309\u201318.\u00a0https:\/\/doi.org\/10.1097\/00000658-199909000-00004.","journal-title":"Ann Surg"},{"issue":"1","key":"11805_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1478-3231.2008.01845.x","volume":"29","author":"R Konopke","year":"2009","unstructured":"Konopke R, Kersting S, Distler M, et al. Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal livermetastases. Liver International. 2009;29(1):89\u2013102.\u00a0https:\/\/doi.org\/10.1111\/j.1478-3231.2008.01845.x.","journal-title":"Liver International"},{"key":"11805_CR16","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1245\/s10434-019-07481-x","volume":"26","author":"D H\u00f6ppener","year":"2019","unstructured":"H\u00f6ppener D, Nierop PMH, van Amerongen MJ, et al. The Disease-free interval between resection of primary colorectal malignancy and the detection of hepatic metastases predicts disease recurrence but not overall survival. Ann Surg. 2019;26:2812\u201320.\u00a0https:\/\/doi.org\/10.1245\/s10434-019-07481-x.","journal-title":"Ann Surg"},{"issue":"8","key":"11805_CR17","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s12094-019-02277-7","volume":"22","author":"GA Colloca","year":"2020","unstructured":"Colloca GA, Venturino A, Guarneri D. Different variables predict the outcome of patients with synchronous versus metachronous metastases of colorectal cancer. Clin Transl Oncol. 2020;22(8):1399\u2013406.\u00a0https:\/\/doi.org\/10.1007\/s12094-019-02277-7.","journal-title":"Clin Transl Oncol"},{"key":"11805_CR18","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1097\/sla.0000000000001593","volume":"263","author":"R Kwakman","year":"2016","unstructured":"Kwakman R, Schrama AM, van Olmen JP, et al. Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases. Ann Surg. 2016;263:1102\u201311.\u00a0https:\/\/doi.org\/10.1097\/sla.0000000000001593.\u00a0","journal-title":"Ann Surg"},{"key":"11805_CR19","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1245\/s10434-019-07294-y","volume":"26","author":"JEKR Hentzen","year":"2019","unstructured":"Hentzen JEKR, Kuipers H, van der Plas WY, et al. Impact of synchronous versus metachronous onset of colorectal peritoneal metastases on survival outcomes after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC): a multicenter, retrospective, Observational Study. Ann Surg Oncol. 2019;26:2210\u201321.\u00a0https:\/\/doi.org\/10.1245\/s10434-019-07294-y.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"11805_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12957-020-1784-4","volume":"18","author":"JSM Wong","year":"2020","unstructured":"Wong JSM, Tan GHC, Chia CS, et al. The importance of synchronicity in the management of colorectal peritoneal metastases with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2020;18(1):10.\u00a0https:\/\/doi.org\/10.1186\/s12957-020-1784-4.","journal-title":"World J Surg Oncol"},{"key":"11805_CR21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374.\u00a0https:\/\/doi.org\/10.1007\/978-1-4613-1247-5_23.","journal-title":"Cancer Treat Res"},{"key":"11805_CR22","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1245\/s10434-013-3145-9","volume":"20","author":"A Kuijpers","year":"2013","unstructured":"Kuijpers A, Mirck B, Aalbers AGJ, et al. Cytoreduction and HIPEC in The Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol. 2013;20:4224\u201330.\u00a0https:\/\/doi.org\/10.1245\/s10434-013-3145-9.","journal-title":"Ann Surg Oncol"},{"key":"11805_CR23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00268-014-2801-y","volume":"39","author":"A Kuijpers","year":"2015","unstructured":"Kuijpers A, Aalbers AGJ, Nienhuijs SW, et al. Implementation of a standardized HIPEC protocol improves outcome for peritoneal malignancy. World J Surg. 2015;39:453\u201360.\u00a0https:\/\/doi.org\/10.1007\/s00268-014-2801-y.","journal-title":"World J Surg"},{"issue":"2","key":"11805_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313.\u00a0https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae.","journal-title":"Ann Surg"},{"key":"11805_CR25","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.1245\/s10434-018-6823-9","volume":"25","author":"M Choudry","year":"2018","unstructured":"Choudry M, Shuai Y, Jones HL, et al. Postoperative complications independently predict cancer-related survival in peritoneal malignancies. Ann Surg Oncol. 2018;25:3950\u20139.\u00a0https:\/\/doi.org\/10.1245\/s10434-018-6823-9.","journal-title":"Ann Surg Oncol"},{"key":"11805_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.critrevonc.2017.03.028","volume":"114","author":"K Rovers","year":"2017","unstructured":"Rovers K, Simkens GA, Punt CJ, van Dieren S, Tanis PJ, de Hingh IH. Perioperative systemic therapy for resectable colorectal peritoneal metastases: sufficient evidence for its widespread use? a critical systematic review. Oncol Hematol. 2017;114:53\u201362.\u00a0https:\/\/doi.org\/10.1016\/j.critrevonc.2017.03.028.","journal-title":"Oncol. Hematol"},{"issue":"1","key":"11805_CR27","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12885-019-5545-0","volume":"19","author":"KP Rovers","year":"2019","unstructured":"Rovers KP, Bakkers C, Simkens GAAM, et al. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). BMC Cancer. 2019;19(1):390.\u00a0https:\/\/doi.org\/10.1186\/s12885-019-5545-0.","journal-title":"BMC Cancer"},{"issue":"3","key":"11805_CR28","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1245\/s10434-015-4892-6","volume":"23","author":"GA Simkens","year":"2016","unstructured":"Simkens GA, van Oudheusden TR, Luyer MD, et al. Predictors of severe morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2016;23(3):833\u201341.\u00a0https:\/\/doi.org\/10.1245\/s10434-015-4892-6.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"11805_CR29","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1245\/s10434-015-5012-3","volume":"23","author":"JM Baumgartner","year":"2016","unstructured":"Baumgartner JM, Kwong TG, Ma GL, et al. A novel tool for predicting major complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(5):1609\u201317.\u00a0https:\/\/doi.org\/10.1245\/s10434-015-5012-3.","journal-title":"Ann Surg Oncol"},{"key":"11805_CR30","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1245\/s10434-014-4297-y","volume":"22","author":"G Simkens","year":"2015","unstructured":"Simkens G, van Oudheusden TR, Luyer MD, et al. Serious postoperative complications affect early recurrence after cytoreductive surgery and hipec for colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2015;22:2656\u201362.\u00a0https:\/\/doi.org\/10.1245\/s10434-014-4297-y.","journal-title":"Ann Surg Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-11805-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-11805-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-11805-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T15:11:45Z","timestamp":1663773105000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-11805-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,5]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["11805"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-11805-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,5]]},"assertion":[{"value":"31 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No conflicts of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The race\/ethnicity distribution was not reported as this data was not collected in the database that was analyzed for this study. Due to the retrospective nature of this study, this data could not be obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Race\/Ethnicity Data"}}]}}